Concepedia

Masahiro Sekimizu

MS

Statistics

Publications

10

Citations

229

H-Index

10

Active since

2013

Affiliations

Nagoya Medical Center(Current)

National Hospital Organization

St. Marianna University School of Medicine

National Hospital Organization Kyushu Cancer Center

Japanese Red Cross Narita Hospital

Masahiro Sekimizu is an author at Nagoya Medical Center specializing in oncology, medicine, and pediatric lymphomas.

ORCID

Publications per year

2013–2021

10

Publications

10

Alectinib for relapsed or refractory anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma: An open‐label phase II trial

Reiji Fukano, Tetsuya Mori, Masahiro Sekimizu et al. · Cancer Science · 2020 · 96 citations · Full text

, , +13

A Case of NUT Midline Carcinoma With Complete Response to Gemcitabine Following Cisplatin and Docetaxel

Hideaki Ueki, Naoko Maeda, Masahiro Sekimizu et al. · Journal of Pediatric Hematology/Oncology · 2013 · 27 citations

, , +12

Prognostic Impact of Intensified Maintenance Therapy on Children With Advanced Lymphoblastic Lymphoma: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group ALB-NHL03 Study

Shosuke Sunami, Masahiro Sekimizu, Tetsuya Takimoto et al. · Pediatric Blood & Cancer · 2015 · 25 citations

, , +12

Characteristics of genetic alterations of peripheral T‐cell lymphoma in childhood including identification of novel fusion genes: the Japan Children’s Cancer Group (JCCG)

Kentaro Ohki, Nobutaka Kiyokawa, Satoru Watanabe et al. · British Journal of Haematology · 2021 · 14 citations · Full text

, , +17

A Phase I/II Study of Crizotinib for Recurrent or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma and a Phase I Study of Crizotinib for Recurrent or Refractory Neuroblastoma : Study Protocol for a Multicenter Single-arm Open-label Trial.

Masahiro Sekimizu, Tomoo Osumi, Reiji Fukano et al. · PubMed · 2018 · 13 citations · Full text

, , +13

1–5 of 10